Introduction & Objectives:
(PCa). In EORTC trial 22961 70 Gy EBRT and 6 months of combined androgen deprivation (SADT arm) was randomly compared to the same treatment followed by 2.5 further years of LH-RH agonist (62% triptoreline) monotherapy (LADT arm), aiming non inferior overall survival (OS) and possibly earlier recovery of testosterone on the SADT-arm Material & Methods: Eligible patients had T1c-2b N1-2 or pN1-2, or T2c-4 N0-2 M0 PCa (UICC 1992) analysis conducted in September 2006, the Independent Data Monitoring Committee recommended interim analysis. OS is compared with the LogRank test.
Results:
biochemical and/or bone progression) occurred in 281 pts (196 on SADT vs. 85 on LADT) and was treated by secondary hormonal manipulation. The 5-year overall survival rate with SADT was 81.1% versus 85.1% with LADT (HR=1.47, 95.7% CI: 1.12-1.94), and failed to prove non-inferiority (the with 5-year event-free rate of 68.7% vs. 80.5% on LADT (HR=1.77, P<0.0001). Likewise, the 5-year biochemical progression-free survival rate was 56.8% on SADT vs. 77.7% on LADT (HR=2.20,
Conclusions:
survival was also shorter with SADT 
EXTERNAL-BEAM RADIATION THERAPY INCREASES THE RATE OF SECONDARY MALIGNANCIES RELATIVE TO RADICAL PROSTATECTOMY IN MEN WITH PROSTATE CANCER

Introduction & Objectives:
external-beam radiation therapy (EBRT) on the rate of secondary malignancies addressed the association between EBRT exposure and secondary malignancies rate in a large administrative database.
Material & Methods:
2004 without neo-or adjuvant hormonal therapy. The diagnosis of bladder, lung and colorectal cancer were established with the ICD-9 and surgery codes, that (cystectomy, lobectomy or pneumectomy and colectomy with or without rectal resection). Univariable and multivariable Cox regression analyses addressed the rate of secondary malignancies (bladder, lung and rectal cancer).
Results: Overall, 92 (0.9%) cystectomies, 82 (0.8%) lung cancer surgeries and 228 (2.2%) surgeries for colorectal cancers were performed. In univariable analyses, the rate of cystectomies (log-rank p=0.002), of treatments for lung cancer (log-rank p<0.001) and for colorectal cancers (log-rank p<0.001) were higher in patients treated with EBRT relative to patients treated with RP. At multivariable analyses, after adjusting for age, baseline comorbidities and year cystectomy for bladder cancer (p=0.04), to a 1.8-fold higher rate of lung cancer resections (p=0.02) and to a 1.7-fold higher rate of rectal cancer (p=0.02).
Conclusions:
The increased rate of secondary malignancies after EBRT should be considered in localized prostate cancer treatment decision-making.
